Seroatlas · Human Serome Atlas

GRAMD2A

GRAM domain-containing protein 2A

Also known as: GRAMD2, GRM2A_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q8IUY3
Gene: GRAMD2A
Ensembl: ENSG00000175318
Chromosome: 15
Canonical length: 354 aa
Protein class: Predicted intracellular proteins, Predicted membrane proteins
Subcellular location: Nucleoli,Nuclear speckles,Cytosol

OverviewNCBI Gene

Enables phosphatidylinositol-4,5-bisphosphate binding activity. Involved in endoplasmic reticulum-plasma membrane tethering and regulation of store-operated calcium entry. Located in endoplasmic reticulum membrane; organelle membrane contact site; and plasma membrane. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

354 residues, UniProt reviewed canonical sequence.

>Q8IUY3|GRAMD2A
     1  MTALSRSEAT EEGGNQQMHR KTASLNSPVS CKEKPDRVEE PPDYSLHWPE GLKGEEIKKC
    61  GREGITLNKY NQQYHKLFKD VPLEEVVLKV CSCALQRDFL LQGRLYISPN WLCFHASLFG
   121  KDIKVVIPVV SVQMIKKHKM ARLLPNGLAI TTNTSQKYIF VSLLSRDSVY DLLRRVCTHL
   181  QPSSKKSLSV REFSGEPESL EVLIPEMKWR KVCPSSRSLS LPDNIPCIPP SSVDSTDSFF
   241  PSRKPPMSEK SRAQVASENG GRWAWPMPGW GPACPKKMPN CSPTAKNAVY EEDELEEEPR
   301  STGELRLWDY RLLKVFFVLI CFLVMSSSYL AFRISRLEQQ LCSLSWDDPV PGHR

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against GRAMD2A can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.54
Highest tissue expression: 46 nTPM

Expression across tissuesHPA

Tissue

placenta: 46 nTPM
epididymis: 34 nTPM
lung: 14 nTPM
breast: 9.6 nTPM
thyroid gland: 8.3 nTPM
seminal vesicle: 4.9 nTPM

Single-cell type

cytotrophoblasts: 223 nCPM
syncytiotrophoblasts: 211 nCPM
ependymal cells: 146 nCPM
migrating cytotrophoblasts: 131 nCPM
alveolar cells type 1: 77 nCPM
epididymal efferent duct ciliated cells: 53 nCPM

Immune cell

myeloid DC: 0.3 nTPM
basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM

Brain region

midbrain: 27 nTPM
medulla oblongata: 21 nTPM
pons: 17 nTPM
hypothalamus: 8.5 nTPM
thalamus: 6.7 nTPM
spinal cord: 5.6 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.36
gnomAD pLI: 0
DepMap mean gene effect: -0.06
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

GRAM domain
PH-like domain superfamily
GRAM domain
GRAM domain-containing protein 2A

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads GRAMD2A as an antibody target. Whether an autoantibody or antibody against GRAMD2A could matter depends on whether native GRAMD2A is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

GRAMD2A is annotated at the cell surface, where native GRAMD2A is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label GRAMD2A as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...